Milvexian for the Prevention of Venous Thromboembolism

A phase 2 trial compared various doses of milvexian with standard enoxaparin for thromboprophylaxis after total knee replacement. Venous thromboembolism occurred in 7 to 8% of patients who received 200 mg of milvexian once or twice daily and in 21% of those who received enoxaparin. The risk of bleed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-12, Vol.385 (23), p.2161-2172
Hauptverfasser:	Weitz, Jeffrey I, Strony, John, Ageno, Walter, Gailani, David, Hylek, Elaine M, Lassen, Michael R, Mahaffey, Kenneth W, Notani, Ravi S, Roberts, Robin, Segers, Annelise, Raskob, Gary E
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adverse events Aged Aged, 80 and over Anticoagulants Anticoagulants - adverse effects Anticoagulants - therapeutic use Anticoagulation Arthroplasty (knee) Arthroplasty, Replacement, Knee Asymptomatic Bleeding Cardiology Coagulation Critical Care Dose-Response Relationship, Drug Drug dosages Enoxaparin - adverse effects Enoxaparin - therapeutic use Factor XIa - antagonists & inhibitors Female Hematology Humans Joint replacement surgery Joint surgery Laboratories Male Middle Aged Oncology Orthopedics Orthopedics General Patients Postoperative Complications - prevention & control Pulmonary Pulmonary embolisms Surgery Surgery General Thromboembolism Thrombosis Veins & arteries Venous Thromboembolism - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A phase 2 trial compared various doses of milvexian with standard enoxaparin for thromboprophylaxis after total knee replacement. Venous thromboembolism occurred in 7 to 8% of patients who received 200 mg of milvexian once or twice daily and in 21% of those who received enoxaparin. The risk of bleeding was similar with milvexian and enoxaparin.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2113194